Clinical severity of Alzheimer's disease is associated with PIB uptake in PET

BACKGROUND The positron emission tomography (PET) tracer [11C]-Pittsburgh Compound-B ([11C]PIB) allows the in vivo assessment of amyloid plaque burden in the brain. In a cross-sectional study we examined the association between the severity of dementia assessed using the Clinical Dementia Rating scale sum of boxes (CDR-SOB) and [11C]PIB-PET in patients with Alzheimer's disease (AD). METHODS Patients with probable AD who had an AD-typical [18F]FDG-PET scan were included. Linear regression analysis in anatomically defined regions-of-interest (ROIs) and correlation analysis using statistical parametric mapping (SPM) were used to determine the association between CDR-SOB and [11C]PIB uptake. RESULTS The linear regression analyses showed that the CDR-SOB explained approximately 11-22% of the variance of [11C]PIB uptake. The association attained statistical significance in both frontal, in both anterior cingulate cortices, and in both putamina. The SPM analysis showed a significant association in more widespread regions of the brain, with maxima located in similar areas as in the ROI-analysis. CONCLUSION The CDR-SOB score is significantly associated with [11C]PIB uptake in patients with AD. Thus [11C]PIB is a potential surrogate marker of dementia severity.

[1]  Lisa A. Weissfeld,et al.  Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.

[2]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[3]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[4]  J. Morris,et al.  Neuropathologic Criteria for Diagnosing Alzheimer Disease in Persons with Pure Dementia of Alzheimer Type , 2004, Journal of neuropathology and experimental neurology.

[5]  G. C. Román,et al.  Vascular dementia , 1993, Neurology.

[6]  Karl J. Friston,et al.  The Relationship between Global and Local Changes in PET Scans , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  A. Nordberg,et al.  Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with Aβ levels , 2008, Neurobiology of Aging.

[8]  K. Davis,et al.  Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. , 1998, Archives of neurology.

[9]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[10]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[11]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[12]  C. Rowe,et al.  Imaging β-amyloid burden in aging and dementia , 2007, Neurology.

[13]  Sanjiv S. Gambhir,et al.  AMIDE: A Free Software Tool for Multimodality Medical Image Analysis , 2003 .

[14]  Markus Schwaiger,et al.  Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease , 2008, NeuroImage.

[15]  L. Jenkins,et al.  Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD , 2005, Neurology.

[16]  U Seligsohn,et al.  Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. , 1997, Clinical chemistry.

[17]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[18]  Satoshi Minoshima,et al.  Imaging Alzheimer's disease: clinical applications. , 2003, Neuroimaging clinics of North America.

[19]  V. Libri,et al.  PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. , 2007, Brain : a journal of neurology.

[20]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[21]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[22]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  P. Hof,et al.  Clinical Validity of Aß‐Protein Deposition Staging in Brain Aging and Alzheimer Disease , 2001 .

[24]  R. Martínez-Murillo,et al.  Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. , 2004, Histology and histopathology.

[25]  P. Hof,et al.  Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease. , 2001, Journal of neuropathology and experimental neurology.

[26]  J. Price,et al.  Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. , 1998, Archives of neurology.

[27]  L A Hansen,et al.  The importance of neuritic plaques and tangles to the development and evolution of AD , 2004, Neurology.

[28]  Brian J Cummings,et al.  β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.

[29]  A. Monsch,et al.  Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease. , 2000, Studies in health technology and informatics.

[30]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[31]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[32]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[33]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[34]  A. Drzezga,et al.  Region-Specific Decline of Cerebral Glucose Metabolism in Patients with Frontotemporal Dementia: A Prospective 18F-FDG-PET Study , 2004, Dementia and Geriatric Cognitive Disorders.

[35]  K. Davis,et al.  Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease , 2006, Neurology.

[36]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.